United Therapeutics says FDA accepts ralinepag NDA
United Therapeutics says the FDA accepted its new drug application for ralinepag to treat pulmonary arterial hypertension and set a PDUFA target action date of June 24, 2027.
UTHR United Therapeutics Corporation announces FDA filing Acceptance of new drug application for ralinepag to treat pulmonary arterial hypertension United Therapeutics Corporation - FDA sets pdufa target action date for ralinepag on June 24, 2027 - Ralinepag has not been approved for use in any indication by FDA and remains investigational for pah